Technology
Health
Biotechnology

Mereo BioPharma Group

$3.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.20 (6.06%) Today
$0.00 (0.00%) As of 3:59 PM EDT after-hours

Why Robinhood?

You can buy or sell MREO and other stocks, options, ETFs, and crypto commission-free!

About MREO

Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease. Read More The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.

Employees
37
Headquarters
London, Greater London
Founded
2015
Market Cap
85.71M
Price-Earnings Ratio
Dividend Yield
Average Volume
15.59K
High Today
$3.59
Low Today
$3.30
Open Price
$3.30
Volume
21.32K
52 Week High
$8.48
52 Week Low
$2.18

Collections

Technology
Health
Biotechnology
Therapy
2019 IPO
UK
Europe
Female CEOs

MREO Earnings

Q2 2019
Estimated
Actual
Expected Aug 19, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.